OptiRTP Meets New Zealand’s Ambassador-Designate to the United States

OptiRTP founders with Ambassador-Designate Chris Seed

Left to right: Bogdan Anich (Founder and Director, OptiRTP), Chris Seed (New Zealand’s Ambassador-Designate to the United States), Jon Doherty (CEO, OptiRTP)

OptiRTP CEO Jon Doherty and Founder and Director Bogdan Anich attended a networking function with Chris Seed, New Zealand’s Ambassador-Designate to the United States, on 4 December 2025.

The event was hosted by the Director of Ministry of Foreign Affairs and Trade (Auckland), Ms Rachel Maidment, in collaboration with the NZUS Council and AmCham NZ. It was held at the MFAT Auckland Office on Quay Street.

Ambassador-Designate Seed, who will take up his post in Washington, D.C. in early 2026, met with representatives from select New Zealand companies that are already operating in the U.S. or preparing for U.S. market entry.

“Anything I can do to help.”

— Chris Seed, Ambassador-Designate to the United States

OptiRTP is planning its U.S. expansion in 2026, with site selection visits to several states scheduled for Q1.

About OptiRTP

OptiRTP (Return to Play) is a New Zealand-based biotech company. Its core technology, OBST (Optimum Bio Sound Therapy), has 352,000+ documented therapy hours with zero serious adverse events reported. OBST is an FDA-registered Class I medical device, 510(k)-exempt (registration and listing, not FDA clearance or approval), that uses dynamic, patterned acoustic neuromodulation via the auditory pathway, with a proposed mechanism involving modulation of central autonomic regulatory networks associated with sleep, pain, recovery and stress regulation. Drug-free and non-invasive, used passively during sleep or rest through a tablet and earbuds. Users can follow recovery markers on their own wearable.

www.optirtp.com

← Back to News